trending Market Intelligence /marketintelligence/en/news-insights/trending/ft1ns3vu7miiv9vrlxy0ea2 content esgSubNav
In This List

Adaptimmune chief technology officer to resign

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Adaptimmune chief technology officer to resign

Adaptimmune Therapeutics plc said Gwen Binder would step down as the company's chief technology officer at the end of January 2019.

Binder was the first U.S. employee of Adaptimmune in 2011, coming from the company's T-cell translational development collaboration program with the University of Pennsylvania.

Abingdon, U.K.-based Adaptimmune operates as a clinical-stage biopharmaceutical company that offers novel cancer immunotherapy products.